SEC Form 4 · accession 0001209191-18-063170
ACHILLION PHARMACEUTICALS INC · ACHN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert L Van Nostrand
Director
Period of report
Dec 14, 2018
Accepted (ET)
Dec 18, 2018 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070336
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 14, 2018 | M | 20,000 | $1.05 | A | 20,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock OptionF1 | $1.05 | Dec 14, 2018 | M | 20,000 | D | — | Dec 15, 2018 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1This option was granted on December 15, 2008 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter.
Remarks
See Exhibit 24.1, Power of Attorney